Pomalyst Patent Protection
3 patents · Celgene Corporation
Patent Details
| Patent # | Title | Assignee | Expires | Status |
|---|---|---|---|---|
| 10555939 | Drug product (formulation / method-of-use) patent (incl. pediatric exclusivity extension) | Celgene Corporation | Nov 19, 2030 | 4.4y left |
| 9993467 | Drug product (formulation / method-of-use) patent (incl. pediatric exclusivity extension) | Celgene Corporation | Nov 19, 2030 | 4.4y left |
| 8828427 | Drug substance & product patent (incl. pediatric exclusivity extension) | Celgene Corporation | Dec 21, 2031 | 5.5y left |
Related Drug Patent Expirations
2 patents · earliest expires 2027 · Celgene Corporation
45 patents · earliest expires 2031 · AbbVie Inc.
1 patents · earliest expires 2031 · Eli Lilly and Company
22 patents · earliest expires 2028 · Pfizer Inc.
5 patents · earliest expires 2032 · AstraZeneca AB
9 patents · earliest expires 2028 · Biogen Inc.
For Pomalyst, the underlying data on this page comes from the FDA Orange Book and USPTO patent records. The breakdown above is the federal record; the paragraphs below add the per-entity context that makes the headline numbers usable for a real decision rather than just a data lookup.
The methodology behind every numeric value on this page is publicly documented on the the FDA Orange Book and USPTO patent records portal and described in detail on this site’s methodology page. Refresh cadence varies by underlying series; the page surfaces the as-of date for each number so readers can trace any figure back to the source release.
Practical use of this page is in combination with the comparison and ranking pages elsewhere on the site, which surface the same data for Pomalyst’s peers within U.S. brand-name drugs. A single-entity reading without peer context can be misleading when an entity is an outlier on one axis but typical on another.